What HKEX Biotech "Step-Ups" Can Tell Us
This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...
343 Views
TOT Biopharm (东曜药业) IPO: Valuation of Core Product TAB008, a Bevacizumab Biosimilar
TOT Biopharm, a China-based clinical-stage biopharmaceutical company, plans to raise at least USD 100 million from its listing in its Hong Kong...
578 Views
ECM Weekly (7 Sep 2019) - China Merchants Comm REIT, Immunotech Bio, Bank of Guizhou, XD, Huize
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
587 Views
TOT Biopharm (东曜药业) IPO: An Unimpressive Pipeline
TOT Biopharm, a China-based clinical-stage biopharmaceutical company, plans to raise at least USD 100 million from its listing on the Hong Kong...
845 Views